Edward A. Motea
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
51
Citations
1,019
Est. group size
—
Recurring co-author estimate
Active years
17
Publishing since 2008
Edward A. Motea studies how cancer cells repair damaged DNA and how those repair processes can be exploited to design more selective cancer treatments. The work focuses on drugs that trigger DNA damage or block repair enzymes (such as PARP inhibitors) so they harm tumor cells while sparing healthy tissue, including in lung, breast, and pancreatic cancers. Projects combine molecular biology, medicinal chemistry, and detection technologies to develop and test new therapeutic and diagnostic agents.
Publication activity has been variable across the decade, with a notable peak in 2023 and roughly 3.6 papers per year on average over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
No award with a current end date on record.
3 earlier awards
- NIH R01CA221158Jun 2017 – Nov 2023 · $356k awarded
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
- NIH R21CA253645Aug 2020 – Aug 2022 · $222k awarded
Development of a novel biochemical tool with tumor-selective theranostic anti-cancer potential
- NIH R01CA210489Jul 2016 – Jun 2022 · $360k awarded
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity
Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.
Typically publishes in teams of ~9 · 9% small-team papers (≤3 authors) · across 14 venues
- Abstract 5943: Development of a <i>SMART</i> theranostic agent for precision pancreatic cancer therapeutics
Cancer Research · 2024
- Supplementary Information from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
2023
- Supplemental Information from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Table S1A-D from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Supplementary Information from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
2023
- Data from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Data from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
2023
- Data from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Data from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
2023
- Table S1A-D from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Supplemental Information from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Supplementary Figure 1 from Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide Reductase
2023
- Supplementary Figure 1 from Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide Reductase
2023
- Data from Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide Reductase
2023
- Data from Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide Reductase
2023
- The FASEB Journal×4
- PMC×3
- Clinical Cancer Research×2
- Cancer Cell×1
- PLoS Genetics×1
- John J. Turchi
Biochemistry, Genetics and Molecular Biology · Indiana University
- Leslie A. Parsels
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Priyanka Verma
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Cody M. Rogers
Biochemistry, Genetics and Molecular Biology · Indiana University
- Eyram Kpenu
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 27, 2026.
Claim or correct this profile